Variable name;level;Overall;Bondy;Clamart;Others;Port Royal;p;test
;n;262;118;80;6;55;;
Age;[0 -30);63;28 (45.2);17 (27.4);2 (3.2);15 (24.2);0.942;
;[30 -35);119;56 (47.9);36 (30.8);3 (2.6);22 (18.8);;
;[35 -40);76;32 (42.1);25 (32.9);1 (1.3);18 (23.7);;
;40+;4;2 (50);2 (50);0 (0);0 (0);;
Number of children;0;177;82 (46.6);47 (26.7);5 (2.8);42 (23.9);0.281;
;1;53;25 (48.1);19 (36.5);1 (1.9);7 (13.5);;
;More than 1;32;11 (35.5);14 (45.2);0 (0);6 (19.4);;
BMI;<18.5;16;9 (56.2);0 (0);0 (0);7 (43.8);0.057;
;25-29.9;46;19 (41.3);20 (43.5);0 (0);7 (15.2);;
;>=30;12;5 (41.7);3 (25);1 (8.3);3 (25);;
;18.5-24.9;181;84 (47.2);52 (29.2);5 (2.8);37 (20.8);;
Treatment center;Curie Paris;168;93 (55.7);24 (14.4);1 (0.6);49 (29.3);<0.001;
;Curie St Cloud;94;25 (27.2);56 (60.9);5 (5.4);6 (6.5);;
Hereditary predisposition;No;159;64 (41);52 (33.3);4 (2.6);36 (23.1);0.054;
;Yes;46;28 (60.9);7 (15.2);2 (4.3);9 (19.6);;
Inflammatory BC;No;260;116 (45.1);80 (31.1);6 (2.3);55 (21.4);0.492;
;Yes;2;2 (100);0 (0);0 (0);0 (0);;
Clinical Tumor size (mm);;32.0 (20.2);31.9 (20.9);36.6 (22.5);32.8 (24.0);25.3 (11.9);0.017;
Clinical N stage (TNM);N0;165;73 (45.1);47 (29);5 (3.1);37 (22.8);0.579;
;N1;96;45 (46.9);32 (33.3);1 (1);18 (18.8);;
SBR grade;Grade I;11;5 (45.5);4 (36.4);1 (9.1);1 (9.1);0.422;
;Grade II;96;40 (41.7);35 (36.5);1 (1);20 (20.8);;
;Grade III;154;72 (47.7);41 (27.2);4 (2.6);34 (22.5);;
Histological type;Lobular;6;2 (33.3);2 (33.3);0 (0);2 (33.3);0.938;
;NST;249;113 (45.7);77 (31.2);6 (2.4);51 (20.6);;
;Others;7;3 (50);1 (16.7);0 (0);2 (33.3);;
Neoajuvant chemotherapy;No;118;48 (41);30 (25.6);4 (3.4);35 (29.9);0.009;
;Yes;144;70 (49.3);50 (35.2);2 (1.4);20 (14.1);;
Chemotherapy setting;Adjuvant;118;48 (41);30 (25.6);4 (3.4);35 (29.9);0.009;
;NAC;144;70 (49.3);50 (35.2);2 (1.4);20 (14.1);;
Fertility preservation discussion;No;3;0 (0);3 (100);0 (0);0 (0);0.079;
;Yes;259;118 (46.1);77 (30.1);6 (2.3);55 (21.5);;
